Event-Driven Stocks

Mural Oncology plc

MURA

Healthcare · Pharmaceutical Preparations · L2 · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 2 warningdetails ↓

Financials

SEC XBRL · annual
 FY24FY23FY22
Revenue———
Operating income−$138.3M−$196.2M−$184.9M
Net income−$128.5M−$207.4M−$189.8M
Total assets$169.4M$301.7M$33.8M
Total liabilities$28.9M$37.9M$55.4M
Equity$140.5M$263.8M−$21.7M
EPS (diluted)$-7.58$-12.43$-11.37
Shares out.16.9M16.7M0

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2024
Operating margin
—
Net margin
—
Return on equity
−91.5%
Return on assets
−75.9%
Return on capital (ROCE)
−96.6%
Liabilities / assets
17.1%
Debt / equity
0.21×
Book value / share
$8.30
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2024
Altman Z″ (distress)
1.46grey zone
Accruals / assets
0.0%clean
Piotroski F-Score
0/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
35
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 33Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 warning● 2 good
  • Negative operating cash flow
  • Altman Z″ in the grey zone
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Nov 28, 2025432,6511.4+3.6%
Nov 14, 2025417,4364.2+1.9%
Oct 31, 2025409,6202.9-3.8%
Oct 15, 2025425,8134.8-2.3%
Sep 30, 2025435,9012.3-22.0%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Corporate family

Spun off from AlkermesALKS · Nov 14, 2023

From the spin-off filings we track. Follow a company to walk its own history.

Event-driven situations (2)